While IGFBP2 expression varied across the spectrum of disease represented by the progression from dysplastic Barrett's esophagus to EAC, a subset of EAC samples expressed very high levels of IGFBP2. We explored whether IGFBP2 in such a subset of tumors might be associated with tumorigenesis or treatment resistance. This evidence concerns the gene IGFBP2 and Barrett esophagus.